| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K90370028 | CTRPv2 | pan-cancer | AAC | -0.0099 | 0.9 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | -0.0048 | 0.9 |
| mRNA | paclitaxel | CTRPv2 | pan-cancer | AAC | 0.0057 | 0.9 |
| mRNA | YK 4-279 | CTRPv2 | pan-cancer | AAC | 0.0054 | 0.9 |
| mRNA | myricetin | CTRPv2 | pan-cancer | AAC | 0.0065 | 0.9 |
| mRNA | BRD-K34222889 | CTRPv2 | pan-cancer | AAC | -0.0051 | 0.9 |
| mRNA | itraconazole | CTRPv2 | pan-cancer | AAC | -0.0062 | 0.9 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0054 | 0.9 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | 0.0055 | 0.9 |
| mRNA | BRD-K09344309 | CTRPv2 | pan-cancer | AAC | -0.013 | 0.9 |